PCT Complete Transdermal (Arimistane + 4-Andro + Enclomiphene + 5a-Hydroxy Laxogenin) – Product Information
PCT Complete is an advanced post-cycle therapy (PCT) research compound formulated to support researchers investigating hormone balance and recovery. By combining Arimistane, 4-Andro, Enclomiphene, and 5a-Hydroxy Laxogenin, PCT Complete offers a comprehensive approach to post-cycle therapy research. It addresses estrogen control, natural testosterone stimulation, muscle preservation, and overall recovery. This blend aims to support hormonal equilibrium, minimize post-cycle research side effects, and optimize natural hormone production research.
- PCT Complete consists of four compounds: Arimistane, 4-Andro, Enclomiphene, and 5a-Hydroxy Laxogenin.
- PCT Complete contains 15mg Arimistane, 15mg 4-Andro, 5mg Enclomiphene, and 2.5mg 5a-Hydroxy Laxogenin, totaling 38mg per ml for 60ml, or 2550mg in total.
Arimistane is an aromatase inhibitor that implies a reduction in the production of estrogen. Aromatase inactivators are bound to the catalytic site, where they are transformed into electrophilic intermediates that become irreversibly attached to the enzyme, blocking its activity. These inhibitors have distinct advantages in compound design because they are highly enzyme-specific, produce prolonged inhibition, and exhibit minimal toxicities. Studies show that Arimistane as an aromatase inhibitor effectively delays epiphysial maturation in young subjects and improves testosterone levels in adult subjects by suppressing the production of estrogen.
4-Andro’s main ingredient, 4-Dehydroepiandrosterone (4-DHEA), is a positional isomer of the DHEA compound. The chemical structural modification of DHEA reduces its thermogenic properties (calorie burning) while increasing its androgenic, anabolic properties and endothelial nitric oxide synthase activity, by increasing its binding affinity to muscular receptors. A recent study on research subjects, on the physiological and hormonal influence of androstenedione, found that during 12 weeks of androstenedione or androstenediol use, a significant increase in the aromatization by-products estrone and estradiol was observed. In the dione group, total testosterone levels significantly increased by 16% after 1 month of use, but by the end of 12 weeks, they returned to pre-treatment levels.
Enclomiphene is an estrogen receptor (ER) modulator. It acts as an ER antagonist in humans, sheep, and rabbits and an ER agonist in rats. Enclomiphene inhibits the binding of 17beta-estradiol in isolated rabbit uteruses. It decreases E2-induced inhibition of follicle-stimulating hormone (FSH) secretion in primary sheep pituitary cells in a concentration-dependent manner. Enclomiphene (0.25 and 0.5 mg/animal) inhibits spermatogenesis and decreases serum luteinizing hormone (LH,) and testosterone levels in intact or castrated rats. Formulations containing enclomiphene have been used in the treatment of ovarian dysfunction. Enclomiphene is being studied for its potential to increase serum-total testosterone levels while maintaining sperm counts in the normal range, in men with secondary hypogonadism.
Known as 5 alpha hydroxy laxogenin or 5a hydroxy laxogenin, laxogenin is a compound derived from a plant and is best known as a member of the compound group collectively referred to as brassinosteroids. While its mechanism of effect has yet to be fully understood, given its status as a brassinosteroid, the prevailing conclusion from preliminary studies to date is the possible effect it can have on the increase of protein synthesis whilst reducing protein breakdown. Laxogenin is also posited to have the ability to enhance muscle growth and recovery, by inhibiting the stress hormone cortisol.